$GITS

Global Interactive Technologies, Inc. (GITS): Entry into a Material Definitive Agreement

Global Interactive Technologies, Inc. (GITS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 25, 2026, between Global Interactive Technologies, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on

Original reporting
Published Jun 30, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$GITS
Neutral
medium confidence
Mentioned
$GITS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GITSNeutralMed
01

Why it matters

The key disclosed economic terms in the excerpt are the common warrant exercise price ($1.83), the exercisability start (6 months after issuance), and the expiration (5.5 years). These terms shape dilution expectations and potential future warrant-driven selling/hedging behavior.

02

Market read

A newly filed definitive financing agreement with warrant terms can reprice dilution risk and drive near-term trading around the capital raise details.

03

What to watch

Traders will want the missing deal-size details (gross proceeds, number of shares/warrants, any investor concentration, and whether there are registration rights or resale restrictions) to judge dilution and selling pressure.

Relevance 6/10Novelty 6/10Timing: today’s SEC 8-K filing (June 30, 2026)

Background

The 8-K indicates GITS entered a Securities Purchase Agreement dated June 25, 2026, under a Regulation D/Section 4(a)(2) exemption, and also references unregistered sales of equity securities.

Company-level read

Ticker impact

$GITSNeutralMedium confidence
Context

GITS filed an 8-K for entry into a securities purchase agreement, including common stock warrants exercisable at $1.83.

Expected impact

Short-term volatility possible around financing/dilution headlines; direction depends on size of proceeds and market appetite, which are not included in the provided excerpt.

Evidence & confidence

This is a primary SEC 8-K disclosure (Item 1.01) with specific warrant exercise price and timing, but the excerpt does not provide total gross proceeds, share count, or net dilution impact.

Market effects

Microcap/small-cap financing via warrant structures can influence sentiment toward similar issuers, but no sector-wide data is provided here.

No clear regional linkage beyond US SEC filing mechanics.

Limited; this is company-specific capital-raise documentation.

Counterpoint

If the placement is small relative to float and proceeds fund near-term catalysts, the warrant overhang may be less price-negative than typical dilutive deals.

Key entities

  • Global Interactive Technologies, Inc.

    Company filing the 8-K and entering the securities purchase agreement.

  • D. Boral Capital LLC

    Named placement agent in the securities purchase agreement excerpt.

  • K&L Gates LLP

    Named company counsel in the agreement excerpt.

Related articles

$GITSLow

Amy Shi named Executive Chair at Global

Global Interactive Technologies, Inc. (GITS) appointed Amy Shi as Executive Chair of the Board, effective October 15, 2026. Shi, 45, has been a director since December 2024 and has over 20 years of experience in business development. She is also the CEO of PixelArc LLC and has held roles at HSBC, JPMorgan Chase, Apple, and China Telecom.

$RCUSHigh

Arcus Biosciences stock falls on public offering announcement

Arcus Biosciences (NYSE:RCUS) shares fell 6.6% in after-hours trading after announcing a public offering of common stock. The company plans to sell shares, with underwriters having a 30-day option for additional shares. Shares had already dropped 20% during regular trading. Citi analyst Yigal Nochomovitz maintained a Buy rating and $50.00 price target, noting clinical trial results met market expectations.